Viewing Study NCT03163667

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:43 AM
Ignite Modification Date: 2026-05-15 @ 11:22 AM
Study NCT ID: NCT03163667
Status: COMPLETED
Last Update Posted: 2022-09-15
First Post: 2017-05-21
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Sponsor: Calithera Biosciences, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Clear Cell Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None advanced, metastatic RCC View
None RCC View
None CB-839 View
None Everolimus View
None CBE View
None Glutaminase Inhibitor View
None Glutaminase View
None Tumor Metabolism View
None Glutamine View